



FORM PTO-1149 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO.: SF0896K	SERIAL NO.: 09/768,917
				APPLICANT: Vicari, et al.	
				FILING DATE: January 24, 2001	GROUP:

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AW	AE WO98/01557	1/15/98				
	AF WO98/14573	4/9/98				
	AG WO97/31098	8/28/97				
	AI WO95/17092	6/29/95				
	AK WO96/34891	11/7/96				
	AL WO94/21277	6/29/94				
	AM WO97/19696	6/5/97				
	AN WO97/41831	11/13/97				
↓	AO WO94/07521	4/14/94				
	AP WO94/13321	6/23/94				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AW	AQ	Fioretti et al., "Reduced Tumorigenicity and Augmented Leukocyte Infiltration After Monocyte Chemotactic Protein-3 Gene Transfer" <i>J. Immunol.</i> 161(1):342-346. (1998)
↓	AR	Dematos et al., 1998, "Pulsing of Dendritic Cells with Cell Lysates from either B16 melanoma or MCA-106 Fibrosarcoma Yields Equally Effective Vaccines Against B16 Tumors in Mice" <i>J. Surg. Oncol.</i> 68(2):79-91.
↓	AS	Vicari et al., 2000, "Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms" <i>J. Immunol.</i> 165:1992-2000.
	AT	
	AU	
	AV	

EXAMINER /Anne Marie Wehbe/ (10/10/2006)	DATE CONSIDERED 10/10/2006
---	-------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail Label: EV 5331X825 US

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no burdens are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 1

<b>Complete If Known</b>	
Application Number	09/768917
Filing Date	01/24/2001
First Named Inventor	VICARI, Alain P
Art Unit	1633
Examiner Name	Anne Marie Sabrina Wehbe
Attorney Docket Number	SF0896KUS

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)			
AW	WO 00/09151		02-24-2000	Schering Corporation	

Examiner /Anne Marie Webbe/ (10/10/2006) Date 10/10/2006

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
SF0896KSERIAL NO.:  
09/768,917INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:  
VICARI et al.FILING DATE:  
January 24, 2001GROUP:  
TO BE ASSIGNED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

RECEIVED  
TECH CENTER 1600  
OCT 8 2001  
2001

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
						YES
AL						
AM						
AN						
AO						
AP						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Youseff, S. et al., 2000, "CC-Chemokine-Encoding DNA Vaccines Enhance Break down of Tolerance to their Gene Products and Treat Ongoing Adjuvant Arthritis" <i>J. Clin. Invest.</i> 106:361-371
AR	Xin, K.Q. et al., 1999, "Immunization of RANTES Expression Plasmid with a DNA Vaccine Enhances HIV-1 Specific Immunity" <i>Clin. Immunol.</i> 92:90-96.
AS	Sin, J. et al., 2000, "DNA Vaccines Encoding Interleukin-8 and RANTES Enhance Antigen-Specific Th1-type (CD4(+)) T-cell-mediated Protective Immunity against Herpes Simplex Virus Type 2 in Vivo." <i>J. Virol.</i> 74:11173-11180.
AT	Nomura, T. et al., 2000, "Chemokines and Anti-cancer Immunotherapy" <i>Anticancer Res.</i> 20:4073-4080.
AU	Lu, Y. et al., 1999, "Macrophage Inflammatory Protein 1 Alpha Expression Plasmid enhances DNA Vaccine-Induced Immune Response Against HIV-1" <i>Clin Exp. Immunol.</i> 115:335-341.
AV	Lillard, J.W. et al., 1999, "Lymphotactin acts as an Innate Mucosal Adjuvant" <i>J. Immunol.</i> 162:1959-1965.

EXAMINER	DATE CONSIDERED
<i>Dee L. Lee</i>	<i>1/11/03</i>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E JAN 28 2001 U.S. PATENT & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SF0896K	SERIAL NO.: 09/768,917
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use several sheets if necessary)</i>				APPLICANT: VICARI et al.	
				FILING DATE: January 24, 2001	GROUP: TO BE ASSIGNED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>AC</i>	AQ	Lehner, T. et al., 2000, "Heat Shock Proteins Generate Beta-Chemokines which Function as Innate adjuvants enhancing Adaptive Immunity" <i>Eur. J. Immunol.</i> 30:594-603.
	AR	Laning, J. et al., 1994, "Inhibition of in Vivo Tumor Growth by the Beta Chemokine, TCA3" <i>J. Immunol.</i> 153:4625-4635.
	AS	Kim, J.J. et al., 2000, "Chemokine Gene Adjuvants can Modulate Immune Responses Induced by DNA Vaccines" <i>J. Interferon Cytokine Res.</i> 20:487-498.
	AT	Braun, S.E. et al., 2000, "The CC Chemokine CK Beta-11/MIP-3 beta/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells through NK Cells" <i>J. Immunol.</i> 164:4025-4031.
<i>AV</i>	AU	Biragyn, A. et al., "Genetic Fusion of Chemokines to Self Tumor Antigen Induces Protective, T-Cell dependent Antitumor Immunity" <i>Nat. Biotechnol.</i> 17:253-258. (1999)
	AV	

EXAMINER	DATE CONSIDERED
<i>See Ober</i>	<i>1/10/05</i>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.